<DOC>
	<DOCNO>NCT00248833</DOCNO>
	<brief_summary>The purpose study determine vaccine call Group B Meningococcal 44/76 MOS NOMV 5D Vaccine safe free side effect protect people meningitis . This study vaccinate three group people . In first 2 group , study double-blinded . This mean neither volunteer medical team know formulation vaccine administer . The third group volunteer medical team know receive high dose vaccine .</brief_summary>
	<brief_title>Safety Immunogenicity Study Group B Meningococcal Vaccine Prevent Meningitis .</brief_title>
	<detailed_description>Meningococcal disease contagious bacterial disease cause Neisseria meningitidis kill child young adult quickly . Meningococci divide distinct sergroups base polysaccharide out capsule , usual target antigen vaccine . Serogroup A main cause epidemic Africa United States , sergroups B , C Y predominate . In United States , vaccine yet available offer protection serogroup B currently account 32 % meningococcal disease United States . This study serve proof concept new NOMV Group B single strain monovalent vaccine model obtain genetically modify parent . If successful plan develop multivalent Group B vaccine routine use military recruit begin basic training , college student , particularly live dormitory , use traveler country recognize hyperendemic disease .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<criteria>Healthy military civilian male nonpregnant , nonlactating female Age 1845 Give inform consent understand risk benefit study Understands willing comply protocol procedure time commitment FEMALES : surgically sterilize receive negative pregnancy test day first injection AND agree practice adequate birth control , necessary , next 7 month first vaccination . Currently history significant organ/system disease History allergy vaccine Allergy component vaccine aluminum hydroxide Presence significant unexplained laboratory abnormality HIV seropositive immunosuppressive state Positive test HBsAg , hepatitis C Ongoing drug abuse/dependence Received live vaccine , experimental product immunosuppressive therapy last 28 day inactivate vaccine past 14 day , receive parenteral immunoglobulin blood product within past 3 month Intention leave study area extend period time study Females : positive urine pregnancy test prior vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>